Cytokinetics (CYTK) Interest & Investment Income (2012 - 2013)
Cytokinetics (CYTK) posted quarterly Interest & Investment Income of $101000.0 for Q4 2013, up 206.06% year-over-year from $33000.0 in Q4 2012, and up 320.83% quarter-over-quarter from $24000.0 in Q3 2013.
Powered by 
Analysis
Cytokinetics (CYTK) Interest & Investment Income (2012 - 2013) Analysis & Trends
Cytokinetics (CYTK) has reported Interest & Investment Income for 2 consecutive years, with $101000.0 the latest figure, recorded in Q4 2013.
- In Q4 2013, Interest & Investment Income rose 206.06% year-over-year to $101000.0; the TTM figure through Dec 2013 stood at $181000.0 (changed N/A YoY), while the FY2015 annual figure was $156000.0, up 44.44% from the prior year.
- Interest & Investment Income rose to $101000.0 in Q4 2013 per CYTK's latest filing, from $24000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $101000.0 in Q4 2013 and bottomed at $13000.0 in Q2 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2013 | 101,000.00 |
| Sep 30, 2013 | 24,000.00 |
| Jun 30, 2013 | 23,000.00 |
| Dec 31, 2012 | 33,000.00 |
| Sep 30, 2012 | 30,000.00 |
| Jun 30, 2012 | 13,000.00 |